NO20042681L - Ny krystallinsk polymorf av venlafaxine-hydroklorid og fremgangsmater for fremstilling derav - Google Patents

Ny krystallinsk polymorf av venlafaxine-hydroklorid og fremgangsmater for fremstilling derav

Info

Publication number
NO20042681L
NO20042681L NO20042681A NO20042681A NO20042681L NO 20042681 L NO20042681 L NO 20042681L NO 20042681 A NO20042681 A NO 20042681A NO 20042681 A NO20042681 A NO 20042681A NO 20042681 L NO20042681 L NO 20042681L
Authority
NO
Norway
Prior art keywords
processes
preparation
venlafaxine hydrochloride
crystalline polymorph
new crystalline
Prior art date
Application number
NO20042681A
Other languages
English (en)
Norwegian (no)
Inventor
Jun Han
Yong Jai Lee
Kadum Abdul Nabi Ali
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20042681L publication Critical patent/NO20042681L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20042681A 2001-12-05 2004-06-25 Ny krystallinsk polymorf av venlafaxine-hydroklorid og fremgangsmater for fremstilling derav NO20042681L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33582201P 2001-12-05 2001-12-05
PCT/US2002/038401 WO2003050075A1 (fr) 2001-12-05 2002-12-03 Nouvelle forme cristalline polymorphe d'hydrochlorure de venlafaxine et methodes de preparation de ladite forme

Publications (1)

Publication Number Publication Date
NO20042681L true NO20042681L (no) 2004-06-25

Family

ID=23313356

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042681A NO20042681L (no) 2001-12-05 2004-06-25 Ny krystallinsk polymorf av venlafaxine-hydroklorid og fremgangsmater for fremstilling derav

Country Status (21)

Country Link
US (2) US7030164B2 (fr)
EP (1) EP1451145A1 (fr)
JP (1) JP2005511736A (fr)
KR (1) KR20050044673A (fr)
CN (1) CN1630631A (fr)
AR (1) AR037744A1 (fr)
AU (1) AU2002348266A1 (fr)
BR (1) BR0214742A (fr)
CA (1) CA2467593A1 (fr)
CO (1) CO5580818A2 (fr)
EC (1) ECSP045136A (fr)
HU (1) HUP0402524A2 (fr)
IL (1) IL162255A0 (fr)
MX (1) MXPA04005305A (fr)
NO (1) NO20042681L (fr)
NZ (1) NZ533363A (fr)
PL (1) PL370552A1 (fr)
RU (1) RU2004120285A (fr)
TW (1) TW200301101A (fr)
WO (1) WO2003050075A1 (fr)
ZA (1) ZA200405248B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183553A1 (en) * 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US6906087B2 (en) * 2000-10-31 2005-06-14 Ciba Specialty Chemicals Corpation Crystalline forms of venlafaxine hydrochloride
KR20070045278A (ko) * 2004-07-22 2007-05-02 와이어쓰 신경계 질환 및 장애의 치료 방법
MX2007000853A (es) * 2004-07-22 2007-03-26 Wyeth Corp Procedimiento para el tratamiento de trastornos y dolencias del sistema nervioso.
US20060020014A1 (en) * 2004-07-22 2006-01-26 Wyeth Method for treating nervous system disorders and conditions
JP2009502798A (ja) * 2005-07-21 2009-01-29 ワイス 神経系障害および状態の処置方法
EP1824815A2 (fr) * 2005-10-19 2007-08-29 Teva Pharmaceutical Industries Ltd. Procede pour preparer de l'hydrochlorure de 1-[2-dimethylamino-(4-methoxyphenyl)ethyl]cyclohexanol tres pur
NZ599480A (en) * 2007-02-21 2013-10-25 Sunovion Pharmaceuticals Inc Solid forms comprising (-)-o-desmethylvenlafaxine and uses thereof
CA2812227C (fr) 2010-10-01 2015-11-24 Shan Dong Luye Pharmaceutical Co., Ltd. Formes polymorphiques du chlorhydrate de 4-methylbenzoate de 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyle, leurs procedes de synthese et leur utilisation
IN2015DN01662A (fr) 2012-09-18 2015-07-03 Auspex Pharmaceuticals Inc
PL3265085T3 (pl) 2015-03-06 2022-11-07 Auspex Pharmaceuticals, Inc. Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
EP1153603B1 (fr) * 1993-06-28 2006-10-18 Wyeth Nouveaux traitements utilisant des dérivés de phenétyle
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
US5530013A (en) * 1994-02-14 1996-06-25 American Home Products Corporation Venlafaxine in the inducement of cognition enhancement
US5506270A (en) * 1995-01-30 1996-04-09 American Home Products Corporation Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
US20020183553A1 (en) * 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
CZ20031298A3 (cs) * 2000-10-19 2003-10-15 Teva Pharmaceutical Industries Ltd. Způsob přípravy krystalické báze venlafaxinu a nových polymorfů hydrochloridu venlafaxinu
US6906087B2 (en) * 2000-10-31 2005-06-14 Ciba Specialty Chemicals Corpation Crystalline forms of venlafaxine hydrochloride
AU2001235970A1 (en) 2000-12-07 2002-06-18 Dr. Reddy's Research Foundation Novel crystalline polymorphic forms of venlafaxine hydrochloride and a process for their preparation
UA77234C2 (en) * 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)

Also Published As

Publication number Publication date
RU2004120285A (ru) 2005-04-10
IL162255A0 (en) 2005-11-20
PL370552A1 (en) 2005-05-30
MXPA04005305A (es) 2004-09-13
JP2005511736A (ja) 2005-04-28
US20030109585A1 (en) 2003-06-12
ZA200405248B (en) 2005-10-03
TW200301101A (en) 2003-07-01
CA2467593A1 (fr) 2003-06-19
AR037744A1 (es) 2004-12-01
US7030164B2 (en) 2006-04-18
EP1451145A1 (fr) 2004-09-01
US20060074131A1 (en) 2006-04-06
WO2003050075A1 (fr) 2003-06-19
BR0214742A (pt) 2004-09-14
CN1630631A (zh) 2005-06-22
AU2002348266A1 (en) 2003-06-23
KR20050044673A (ko) 2005-05-12
HUP0402524A2 (hu) 2005-03-29
NZ533363A (en) 2005-10-28
CO5580818A2 (es) 2005-11-30
ECSP045136A (es) 2004-07-23

Similar Documents

Publication Publication Date Title
AP1830A (en) Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same.
NO329883B1 (no) Fremgangsmate for fremstilling av prostaglandiner og analoger derav og av mellomforbindelser, og forbindelser fremstilt derved
NO20052676L (no) Polymorfer av bicifadin-saltsyre
DK1446380T3 (da) Formoteroltartrafremgangsmåde og polymorf
NO20040680D0 (no) Nye dihydropterinonerfremgangsmate for fremstilling derav og deres anvendelse som legemiddel
NO20040794L (no) (-)-1-(3,4-Diklorfenyl)-3-azabicyklo[3.1.0]heksan, forbindelser derav og anvendelser som en dopamin-gjenopptaks-inhibitor.
NO20042681L (no) Ny krystallinsk polymorf av venlafaxine-hydroklorid og fremgangsmater for fremstilling derav
HK1078315A1 (en) Synthesis of 2-hydroxy-n,n-dimethyl-3- 2- 1(r)-(5-methyl-2-furanyl)propyl amino -3,4-dioxo-1-cyclobuten- 1-yl amino benzamide
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
NO20034236D0 (no) Ny fremgangsmåte for den industrielle syntese av tetraestere av 5-[bis(karboksymetyl)amino]-3-karboksymetyl-4-cyano-2-tiofenkarboksylsyre, oganvendelse isyntesen av bivalente salter av ranelinsyre og deres hydrater
NO20040388L (no) Fremgangsmåte for fremstilling av beraprost og salter derav, samt forbindelser som er mellomprodukter i fremgangsmåten
NO20050885D0 (no) Ny fremgangsmate for syntesen av 1,3-dihydro-2H-3-benzazepin-2-onforbindelser, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
HUP0700037A2 (en) Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
TR200503401T1 (tr) Kuetiapin (Quetiapine) Fumarat'ın yeni polimorfları
RS52260B (en) N- (2-hydroxyethyl) -N-methyl-4- (quinoline-8-yl (1- (thiazol-4-ylmethyl) piperidin-4-ylidene) methyl) benzamide, a process for its production as well as its use for treatment PAIN, TENSION AND DEPRESSION
HUP0402553A2 (hu) Venlafaxin-hidroklorid-monohidrát, eljárások előállítására, az ezt tartalmazó gyógyszerkészítmények és alkalmazásuk
BRPI0411652A (pt) processo para a preparação de derivados de espirobenzoazepina substituìdos não-peptìdicos
NO20055495L (no) 4-(4-trans-hydroksysykloheksyl)amino-2-fenyl-7H-pyrrolo[2,3-d]-pyrimidinhydrogenmesylat og dets polymorfe former
HUP0400767A2 (hu) Javított eljárás tiszta ondansetron-hidroklorid-dihidrát előállítására
NO20043047L (no) Mellomprodukter for LHRH-antagonistsyntese, fremgangsmate for fremstilling derav og fremgangsmate for LHRH-antagonistfremstilling
HUP0101609A2 (hu) Eljárás peszticid intermedierek előállítására
EP1406614A4 (fr) Polymorphe de carvedilol
EA200300771A1 (ru) Новая соль бензоилгуанидина
MXPA04003478A (es) Sintesis de (4-bromofenil)(4-piperidil)metanona-(z)-o-etiloxima y sales.
WO2004069790A3 (fr) Modification cristalline

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application